Guotai Hong Kong Morning Brief | 2026 National Basic Medical Insurance Drug List Adds 107 Medicines; Fed Official Signals More Rate Hikes

Stock News11-16 08:05

2026 Edition of the National Basic Medical Insurance Drug List Released, Adding 107 Medicines

The 2026 edition of the national medical insurance drug list was released on November 14, 2026, adding 107 medicines, of which 51 are Class 1 innovative drugs, setting a new record high. The new list will officially take effect on January 1, 2027.

Highlights of this round: 1. CAR-T included in basic medical insurance for the first time: JW Therapeutics' relma-cel injection became the first CAR-T product to enter the national medical insurance list. Originally priced at over one million yuan, patients' out-of-pocket costs after reimbursement are expected to fall below 100,000 yuan. 2. Non-factor drugs for hemophilia included: fitusiran sodium, emicizumab and others fill gaps in the list. 3. Domestic innovative drugs performed prominently: Innovent Biologics' mazdutide (the first domestically developed dual-target weight-loss and glucose-lowering original drug), Baili Tianheng's Yizekang (included in its first year on the market), and Henlius' Hansizhuang all had products included. 4. Payment cap for ophthalmic drugs raised: the medical insurance payment limit for two anti-VEGF ophthalmic drugs was adjusted from "a maximum of 9 doses per eye cumulatively" to "14 doses," the first increase in nine years. 5. Assisted reproductive drugs included for the first time: injectable human follicle-stimulating hormone alpha and luteinizing hormone alpha entered the list. This year, the commercial health insurance innovative drug list was also adjusted in parallel, adding 12 medicines (including the world's first solid tumor CAR-T and China's first hemophilia gene therapy drug), bringing the total to 28. A linkage mechanism between the commercial insurance list and the basic medical insurance list has also been established, with 2 drugs from the 2025 commercial insurance list transferred to basic medical insurance this year.

Market Outlook: Nasdaq Rose 2.27% Last Week; Nvidia Fell 13% for Its Largest Weekly Drop Since April 2025

In overnight U.S. trading, the Dow Jones Industrial Average rose 50.46 points to close at 52,347.55, up 0.1%; the S&P 500 fell 30.73 points to close at 7,561.67, down 0.4%; the Nasdaq Composite fell 229.82 points to close at 25,136.27, down 0.91%. The Dow gained 2.07% last week, the Nasdaq rose 2.27% last week, and the S&P 500 gained 2.51% last week. Among the "Magnificent Seven" tech giants, Meta Platforms rose 2.90%, Apple rose 0.39% to a record closing high; Nvidia fell over 2%, bringing its cumulative weekly decline to 13%, the largest single-week drop since April 2025 and its sixth consecutive weekly decline, the longest losing streak since 2012, with over $573 billion in market value erased last week. Chip stocks declined, with the Philadelphia Semiconductor Index falling 3.43%; AMD dropped over 8%, SanDisk fell over 5%, Western Digital dropped 5%, Broadcom and ARM fell over 4%, and Lam Research and Seagate Technology fell over 3%. The Nasdaq Golden Dragon China Index rose 0.84%, with popular Chinese concept stocks trading mixed. Hong Kong's Hang Seng Index ADR rose, closing at 23,729.90 on a proportional basis, up 92.30 points or 0.39% from the Hong Kong close. On the New York Mercantile Exchange, the front-month WTI crude oil futures contract rose $0.37 to $89.11 per barrel, up 0.42%. COMEX front-month gold futures fell $5.30, or 0.14%, to $3,880.0 per ounce.

Hotspot Preview: After Inflation Exceeded Expectations, Fed's Collins Says Further Rate Hikes Needed Soon

Boston Fed President Susan Collins said that as inflationary pressures spread to more areas, the Federal Reserve will "soon" need to raise interest rates further. However, she did not specify the magnitude or pace of the hikes, nor did she directly respond to whether she supports a 50 basis point increase in December. Chicago Fed President Austan Goolsbee said on Friday that the latest inflation data is concerning and the Fed may still need to take further action to curb price increases and rebuild market confidence in the central bank's ability to control inflation. Goolsbee said in an interview that day: "I think the Fed clearly has a lot of work to do to continue rebuilding its credibility."

Foreign Exchange Deposit Reserve Ratio Raised to 6%

On November 15, the People's Bank of China's increase of the foreign exchange deposit reserve ratio for financial institutions officially took effect, raising it from the current 4% to 6%. This increase helps promote supply-demand balance in the foreign exchange market and break the self-fulfilling expectation of RMB appreciation.

Guotai Haitong Asset Management Clarifies False Information Circulating Online: Never Conducted Trades with Private Funds as Counterparties

Recently, rumors circulated online about "an institution entrusting funds to a certain company for advisory management, conducting negotiated repurchase transactions with private funds and defaulting on repurchases." In response, Guotai Haitong Asset Management issued an announcement on November 14 clarifying that the online content is unrelated to Shanghai Guotai Haitong Securities Asset Management Co., Ltd., and the business described online was not conducted by Guotai Haitong Asset Management. Guotai Haitong Asset Management has long prohibited any form of cash bond or repurchase business with private funds and has never conducted transactions with private funds as counterparties. Guotai Haitong Asset Management adheres to independent investment decision-making and execution, has established strict access, approval and risk control mechanisms, and does not engage in the business described in the online rumors.

JW Therapeutics-B (02126) Plans to Issue Approximately 61.1855 Million Subscription Shares at a Discount of About 2.97%, Raising HK$160 Million

JW Therapeutics-B (02126) announced that on November 15, 2026, the company entered into subscription agreements with China Hongqiao Holding Co., Ltd. or its designated entity and Novo Vista Limited Partnership, to issue a total of approximately 61.1855 million subscription shares at HK$2.615 per subscription share, a discount of about 2.97% to the closing price of HK$2.695 per share as quoted on the Stock Exchange on the last trading day, with total subscription proceeds of HK$160 million.

China Development Bank Financial Leasing (01606) Plans to Purchase IT Computer Equipment for 981 Million Yuan

China Development Bank Financial Leasing (01606) announced that as buyer, it entered into a product procurement agreement with the seller (Guangdong Shuhuan Zhilian Technology Co., Ltd.) on November 13, 2026, under which the seller agreed to sell and the buyer agreed to purchase the procurement subject for a total consideration of approximately RMB 981 million. The procurement subject is IT computer equipment.

China Boton (03318) Subsidiary to Inject 160 Million Yuan into Shandong Ganghong Biotechnology to Acquire 49% Equity

Upon completion, Shenzhen Boton will hold 49% of the enlarged registered capital of the target company. Accordingly, the target company will be accounted for as an associate of the company, and its financial results will not be consolidated into the group's consolidated financial statements.

Xinhua Winshare (00811) Acquires 100% Equity of Sichuan Nationalities Publishing House Co., Ltd.

The company received notice from Sichuan Xinhua Publishing and Distribution Group that this transaction has been approved by the higher-level state-owned asset regulatory authority.

China Education Group (00839) Expects Annual Net Profit Attributable to Shareholders of Approximately 630 Million to 770 Million Yuan

The above expected results have taken into account expected non-cash impairment losses (net of deferred tax) of approximately RMB 1.06 billion to RMB 1.14 billion, involving certain non-current assets of two cash-generating units located in Henan Province and Sichuan Province, mainly reflecting downward revisions to estimated future cash flows due to changes in market conditions and business plans.

Zhaoke Ophthalmology-B (06622): Independently Developed Innovative Drug Jingyouting (Cyclosporine Ophthalmic Gel) Receives Marketing Approval from the National Medical Products Administration

The indication is to promote tear secretion in patients with dry eye disease, suitable for patients with reduced tear production caused by dry eye, to improve their ocular signs.

Hansoh Pharmaceutical (03692): Aumolertinib Marketing Authorization Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use

Hansoh Pharmaceutical (03692) announced that on November 12, 2026, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of marketing authorization for aumolertinib for the treatment of non-small cell lung cancer.

TCL Electronics (01070) Reports Strong Growth in First Three Quarters; Adjusted Net Profit Attributable to Parent of HK$2.243 Billion, Up 54.5% Year-on-Year

In the first three quarters of 2026, the group's internet business revenue grew 28.2% year-on-year to HK$2.695 billion. Among this, the higher-margin international internet business continued to accelerate its expansion, with its revenue share of internet business revenue rising 17.0 percentage points year-on-year, driving the overall internet business gross margin up 4.6 percentage points year-on-year to 60.9%, continuing to contribute high-quality profits.

Stock Spotlight: IMPACT Therapeutics-B (07630): EU Marketing Application for Senaparib Expected to Be Approved This Month

IMPACT Therapeutics announced that the board has decided to use no more than HK$100 million to repurchase H shares on the open market, with all funds coming from the company's own resources. In addition, the company may, depending on market conditions, further repurchase H shares within the repurchase authorization granted by the shareholders' meeting. Notably, senaparib received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in September. Goldman Sachs stated that IMPACT Therapeutics management indicated at the GS Asia Healthcare Corporate Day that the EU marketing application for senaparib is expected to be approved this month, based on the positive CHMP opinion received in September.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment